Literature DB >> 12942406

Duration of highly active antiretroviral therapy regimens.

Ray Y Chen1, Andrew O Westfall, Michael J Mugavero, Gretchen A Cloud, James L Raper, Ashlee G Chatham, Edward P Acosta, Kelly H Taylor, Jerome Carter, Michael S Saag.   

Abstract

The median duration of highly active antiretroviral therapy (HAART) regimens was reported to be 11.8 months in one US study, but that study included both treatment-experienced and treatment-naive patients. The duration of initial HAART regimens for treatment-naive patients alone has not been reported. We selected 405 antiretroviral-naive patients who were seen at the University of Alabama at Birmingham HIV Outpatient Clinic from 1 January 1996 through 9 October 2001, and we assessed the duration of initial and successive HAART regimens in this group. Any antiretroviral medication change, excluding dosage changes, that lasted >or=14 days was considered to indicate the start of a new regimen. The median duration of regimens was determined by Kaplan-Meier analysis, and proportional hazards regression was used to identify factors associated with shorter duration of initial regimen. The median duration of initial regimens was 1.6 years, and medication toxicity-associated events were the cause of one-half of discontinuations. Only a history of opportunistic infection and injection drug use were significantly associated with shorter regimen duration.

Entities:  

Mesh:

Year:  2003        PMID: 12942406     DOI: 10.1086/377271

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  26 in total

Review 1.  Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature.

Authors:  Albert M L Anderson; John A Bartlett
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

2.  Durability of adherence to antiretroviral therapy on initial and subsequent regimens.

Authors:  Edward M Gardner; William J Burman; Moises E Maravi; Arthur J Davidson
Journal:  AIDS Patient Care STDS       Date:  2006-09       Impact factor: 5.078

3.  Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection.

Authors:  Eric S Rosenberg; Marie Davidian; H Thomas Banks
Journal:  Drug Alcohol Depend       Date:  2007-02-05       Impact factor: 4.492

4.  Abstracts of the HIV & Hepatitis in the Americas 2017 - Congress.

Authors: 
Journal:  J Int AIDS Soc       Date:  2017-04-06       Impact factor: 5.396

5.  Increased Persistence of Initial Treatment for HIV Infection With Modern Antiretroviral Therapy.

Authors:  Thibaut Davy-Mendez; Joseph J Eron; Oksana Zakharova; David A Wohl; Sonia Napravnik
Journal:  J Acquir Immune Defic Syndr       Date:  2017-10-01       Impact factor: 3.731

6.  Validation of an algorithm to identify antiretroviral-naïve status at time of entry into a large, observational cohort of HIV-infected patients.

Authors:  Neel R Gandhi; Janet P Tate; Maria C Rodriguez-Barradas; David Rimland; Matthew Bidwell Goetz; Cynthia Gibert; Sheldon T Brown; Kristin Mattocks; Amy C Justice
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-07-09       Impact factor: 2.890

7.  Effect of persistency of first-line HIV antiretroviral therapy on clinical outcomes.

Authors:  James H Willig; Andrew O Westfall; Michael Mugavero; Christa R Nevin; Todd Correll; Amit Duggal; William Guyer; Michael S Saag; Timothy Juday
Journal:  AIDS Res Hum Retroviruses       Date:  2012-12-18       Impact factor: 2.205

8.  Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.

Authors:  James H Willig; Sarah Abroms; Andrew O Westfall; Justin Routman; Sunil Adusumilli; Mohit Varshney; Jeroan Allison; Ashlee Chatham; James L Raper; Richard A Kaslow; Michael S Saag; Michael J Mugavero
Journal:  AIDS       Date:  2008-10-01       Impact factor: 4.177

9.  Antiretroviral Regimen Durability and Success in Treatment-Naive and Treatment-Experienced Patients by Year of Treatment Initiation, United States, 1996-2011.

Authors:  Anandi N Sheth; Ighovwerha Ofotokun; Kate Buchacz; Carl Armon; Joan S Chmiel; Rachel L D Hart; Rose Baker; John T Brooks; Frank J Palella
Journal:  J Acquir Immune Defic Syndr       Date:  2016-01-01       Impact factor: 3.731

10.  Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems.

Authors:  T W Kim; A Palepu; D M Cheng; H Libman; R Saitz; J H Samet
Journal:  AIDS Care       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.